A system and method for purifying coenzyme Q.sub.10 are provided. The method includes: passing a CoQ.sub.10-containing crude product through a first chromatographic column to obtain a first CoQ.sub.10-containing intermediate product. The method further includes preparing, based on the first CoQ.sub.10-containing intermediate product, a second CoQ.sub.10-containing intermediate product. The method further includes passing the second CoQ.sub.10-containing intermediate product through a second chromatographic column to obtain a third CoQ.sub.10-containing intermediate product. The method further includes obtaining purified CoQ.sub.10 product by purifying the third CoQ.sub.10-containing intermediate product.

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

An efficient production method for obtaining a reduced coenzyme Q10 Form II-type crystal having a stable crystal form is disclosed. The production method includes adding a seed crystal of a Form II-type crystal to a solution including ethanol and reduced coenzyme Q10; and precipitating a Form II-type crystal, wherein a dissolved concentration C.sub.i of reduced coenzyme Q10 before adding the seed crystal is equal to or more than a saturated concentration of a Form II-type crystal and less than a saturated concentration of a Form I-type crystal at a temperature T.sub.i when adding the seed crystal. The crystal precipitation step may include controlling a temperature T.sub.p of the solution so that a dissolved concentration C.sub.p of reduced coenzyme Q10 is equal to or more than the saturated concentration of the Form II-type crystal and less than the saturated concentration of the Form I-type crystal.

An efficient production method for obtaining a reduced coenzyme Q10 Form II-type crystal having a stable crystal form is disclosed. The production method includes adding a seed crystal of a Form II-type crystal to a solution including ethanol and reduced coenzyme Q10; and precipitating a Form II-type crystal, wherein a dissolved concentration C.sub.i of reduced coenzyme Q10 before adding the seed crystal is equal to or more than a saturated concentration of a Form II-type crystal and less than a saturated concentration of a Form I-type crystal at a temperature T.sub.i when adding the seed crystal. The crystal precipitation step may include controlling a temperature T.sub.p of the solution so that a dissolved concentration C.sub.p of reduced coenzyme Q10 is equal to or more than the saturated concentration of the Form II-type crystal and less than the saturated concentration of the Form I-type crystal.

The invention relates to processes for preparing 2-methoxymethyl-p-phenylenediamine (I), cosmetically acceptable salts thereof, or mixtures thereof.

The invention relates to processes for preparing 2-methoxymethyl-p-phenylenediamine (I), cosmetically acceptable salts thereof, or mixtures thereof.

A nanomaterial includes a ZnO nanocrystal and a surface ligand bonded to the ZnO nanocrystal. The surface ligand has a structure of

##STR00001##

R.sup.1, R.sup.2, and R.sup.3 are independently selected from at least one of an alkyl group, an alkoxy group, a hydroxyalkoxy group, a hydroxyl group, or a hydrogen atom. R.sup.4 is selected from a hydrocarbon group having a carbon number of 5 to 60. A carbon number of the alkyl group ranges from 1 to 5. A carbon number of the alkoxy group ranges from 1 to 5. A carbon number of the hydroxyalkoxy group ranges from 1 to 5.

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

The present application relates to a method for extracting coenzyme Q10 and a phospholipid from a coenzyme Q10 fermentation bacterium powder. The method is characterized in that the fermentation bacterium powder of a coenzyme Q10 production strain is subjected to extraction with a mixed solvent of which the three-dimensional Hansen solubility parameter is between 21 and 23 (J/cm.sup.3).sup.1/2 and the hydrogen bonding solubility parameter thereof is between 10 and 12 (J/cm.sup.3).sup.1/2. The present invention can efficiently extract two products, namely coenzyme Q10 and a phospholipid, from the coenzyme Q10 fermentation bacterium powder; the process thereof is highly operable, easy to be industrialized, and can provide a product with high purity and yield, having great economic benefit.